Enhanced contractility of renal afferent arterioles from angiotensin-infused rabbits: Roles of oxidative stress, thromboxane prostanoid receptors, and endothelium

Circulation Research

Volumn 94, Issue 11, 2004, Pages 1436-1442

  Wang, Dan ^a   Chabrashvili, Tina ^a   Wilcox, Christopher S ^a,b  

^a GEORGETOWN UNIVERSITY   (United States)

^b GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cyclooxygenase; Endothelium derived contraction factor; Endothelium derived relaxation factor; Nitric oxide; Reactive oxygen species; Superoxide anion; Tempol; Thromboxane A2

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 5 (4 CHLOROPHENYL) 1 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOLE; ANGIOTENSIN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; ENDOTHELIUM DERIVED CONSTRICTING FACTOR; ENDOTHELIUM DERIVED RELAXING FACTOR; IFETROBAN; MESSENGER RNA; NITRIC OXIDE; OZAGREL; PARECOXIB; PROSTAGLANDIN SYNTHASE; PROSTANOID RECEPTOR; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; TEMPOL; THROMBOXANE SYNTHASE;

ANIMAL TISSUE; ARACHIDONIC ACID METABOLISM; ARTERY CONSTRICTION; ARTICLE; BLOOD PRESSURE REGULATION; BLOOD VESSEL DIAMETER; CONTROLLED STUDY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RABBIT; RENAL ARTERY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; VASCULAR ENDOTHELIUM; VASOCONSTRICTION;

15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID; 8,11,14-EICOSATRIENOIC ACID; ANGIOTENSIN II; ANIMALS; ARTERIOLES; BICYCLO COMPOUNDS, HETEROCYCLIC; CYCLIC N-OXIDES; CYCLOOXYGENASE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIN-1; ENDOTHELINS; ENDOTHELIUM, VASCULAR; ISOENZYMES; KIDNEY; MALE; NITROARGININE; NOREPINEPHRINE; OXAZOLES; OXIDATIVE STRESS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRAZOLES; RABBITS; RECEPTORS, THROMBOXANE; RNA, MESSENGER; SPIN LABELS; SUPEROXIDES; VASCULAR RESISTANCE; VASOCONSTRICTION;

EID: 2942711439     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.0000129578.76799.75     Document Type: Article

References (52)

1. Ames RP, Borkowski AJ, Sicinski AM, Laragh JH. Prolonged infusions of angiotensin II and norepinephrine and blood pressure, electrolyte balance, aldosterone and cortisol secretion in normal man and in cirrhosis with ascites. J Clin Invest. 1965;44:1171-1186.
2. Dickinson CJ, Yu R. Mechanisms involved in the progressive pressor response to very small amounts of angiotensin II in conscious rabbits. Circ Res. 1967;XX and XISuppl II:II-157-II-163.
3. Kawada N, Imai E, Karber A, Welch WJ, Wilcox CS. A mouse model of angiotensin II slow pressor response: role of oxidative stress. J Am Soc Nephrol. 2002;13:2860-2868.
4. Lever AF. The fast and slow developing pressor effect of angiotensin II. The renin-angiotensin system. In: Robertson JIS, Nicholls MG, eds. London: Gower Medical Publishing; 1993.
5. Imig JD. Afferent arteriolar reactivity to angiotensin II is enhanced during the early phase of angiotensin II hypertension. Am J Hypertens. 2000;13:810-818.
6. Wang D, Chen Y, Chabrashvili T, Aslam S, Borrego L, Umans J, Wilcox CS. Role of oxidative stress in endothelial dysfunction and enhanced responses to Ang II of afferent arterioles from rabbits infused with Ang II. J Am Soc Nephrol. 2003;14:2783-2789.
7. Fukui T, Ishizaka N, Rajagopalan S, Laursen JB, Capers IQ, Taylor WR, Harrison DG, Leon H, Wilcox JN, Griendling KK. p22phox mRNA expression and NADPH oxidase activity are increased in aortas from hypertensive rats. Circ Res. 1998;80:45-51.
8. Laursen JB, Rajagopalan S, Galis Z, Tarpey M, Freeman BA, Harrison DG. Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension. Circ. 1997;95:588-593.
9. Ortiz MC, Manriquez MC, Romero JC, Juncos LA. Antioxidants block angiotensin II-induced increases in blood pressure and endothelin. Hypertens. 2001;38:655-659.
10. Wang D, Borrego-Conde L, Falck JR, Sharma KK, Wilcox CS, Umans JG. Contributions of NO, EDHF and EETs to endothelium-dependent relaxation in rabbit renal afferent arterioles. Kidney Int. 2003;63:2187-2193.
11. Chabrashvili T, Kitiyakara C, Blau J, Karber A, Aslam S, Welch WJ, Wilcox CS. Effects of Ang II type 1 and type 2 receptors on oxidative stress, renal NADPH oxidase and SODs expression. Am J Physiol Regul Integr Comp Physiol. 2003;285:R117-R124.
12. Luft FC, Wilcox CS, Unger T, Kuhn R, Demmert G, Rohmeiss P, Ganten D, Sterzel RB. Angiotensin-induced hypertension in the rat: Sympathetic nerve activity and prostaglandins. Hypertens. 1989;14:396-403.
13. Wang D, Chabrashvili T, Chen Y, Wilcox CS. Distinct effects of TP receptors and oxidative stress in contractile responses of afferent arterials from Ang II-infused rabbits. Hypertens. 2003;42:401.
14. Wilcox CS, Welch WJ. Thromboxane synthase and TP receptor mRNA in rat kidney and brain: effects of salt intake and Ang II. Am J Physiol Renal Physiol. 2003;284:F525-F531.
15. Kawada N, Dennehy K, Moriyama T, Imai E, Welch W, Wilcox CS. Thromboxane A2 and thromboxane A2-prostaglandin H2 receptors regulate renal hemodynamics during angiotensin II slow pressor response. J Am Soc Nephrol. 2003;14:611A.
16. Keen HL, Brands MW, Smith MJ, Shek EW, Hall JE. Thromboxane is required for full expression of angiotensin hypertension in rats. Hypertens. 1997;29:310-314.
17. Ogletree ML, Harris DH, Schumacher WA, Webb ML, Misra RN. Pharmacological profile of BMS 180,219: A potent, long-acting, orally active thromboxane A2/prostaglandin endoperoxide receptor antagonist. J Pharmacol Exp Ther. 1993;264:570-578.
18. Wilcox CS, Welch WJ. Thromboxane mediation of the pressor response to infused angiotensin II. Am J Hypertens. 1990;3:242-249.
19. Wilcox CS, Welch WJ, Snellen H. Thromboxane mediates renal hemodynamic response to infused angiotensin II. Kidney Int. 1991;40:1090-1097.
20. Auch-Schwelk W, Katusic ZS, Vanhoutte PM. Thromboxane A2 receptor antagonists inhibit endothelium-dependent contractions. Hypertens. 1990;15:699-703.
21. Hibino M, Okumura K, Iwama Y, Mokuno S, Osanai H, Matsui H, Toki Y, Ito T. Oxygen-derived free radical-induced vasoconstriction by thromboxane A2 in aorta of the spontaneously hypertensive rat. J Cardiovasc Pharmacol. 1999;33:605-610.
22. Ito S, Carretero OA. Impaired response to acetylcholine despite intact endothelium-derived relaxing factor/nitric oxide in isolated perfused afferent arterioles of the spontaneously hypertensive rat. J Cardiovasc Pharmacol. 1992;20:S187-S189.
23. Lin L, Nasjletti A. Role of endothelium-derived prostaglandin in angiotensin-induced vasoconstriction. Hypertens. 1991;18:158-164.
24. Noll G, Lang MG, Tschudui MR, Ganten D, Luscher TF. Endothelial vasoconstrictor prostanoids modulate contractions to acetylcholine and Ang II in ren-2-rats. Am J Physiol. 1997;272:H493-H500.
25. Pomposiello S, Yang X-P, Liu Y-H, Surakanti M, Rhaleb N-E, Sevilla M, Carretero OA. Autocoids mediate coronary vasoconstriction induced by nitric oxide synthesis inhibition. J Cardiovasc Pharmacol. 1997;30:599-606.
26. Tesfamariam B, Jakubowski JA, Cohen RA. Contraction of diabetic rabbit aorta caused by endothelium-derived PGH2-TxA2. Am J Physiol. 1989;257:H1327-H1333.
27. Tesfamariam B, Cohen RA. Role of superoxide anion and endothelium in vasoconstrictor action of prostaglandin endoperoxide. Am J Physiol. 1992;262:H1915-H1919.
28. Yang D, Feletou M, Boulanger CM, Wu HF, Levens N, Zhang JN, Vanhoutte PM. Oxygen-derived free radicals mediate endothelium-dependent contractions to acetylcholine in aortas from spontaneously hypertensive rats. Br J Pharmacol. 2002;136:104-110.
29. McGiff JC, Quilley J. 20-HETE and the kidney: resolution of old problems and new beginnings. Am J Physiol. 1999;277:R607-R623.
30. Bulut D, Liaghat S, Hanefeld C, Koll R, Miebach T, Mugge A. Selective cyclooxygenase-2 inhibition with parecoxib acutely impairs endothelium-dependent vasodilation in patients with essential hypertension. J Hypertens. 2003;21:1663-1667.
31. Krishna CM, Russo A, Mitchell JB, Goldstein S, Dafni H, Samuni A. Do nitroxides antioxidants act as scavengers of O2.- or as SOD mimics? J Biol Chem. 1996;271:26026-26031.
32. Okumura M, Imanishi M, Hosoi M, Okada N, Morikawa T, Miura K, Nakatani T, Fujii S. Role of thromboxane A2 from glomerular thrombi in nephropathy with type 2 diabetic rats. Life Sci 2003;72:2695-2705.
33. Potenza MA, Botrugno OA, De Salvia MA, Lerro G, Nacci C, Marasciulo FL, Andriantsitohaina R, Mitolo-Chieppa D. Endothelial COX-1 and -2 differentially affect reactivity of MVB in protal hypertensive rats. Am J Physiol Gastrointest Liver Physiol. 2002;283:G587-G594.
34. Schnackenberg CG, Welch WJ, Wilcox CS. TP receptor-mediated vasoconstriction in microperfused afferent arterioles: role O2- and NO. Am J Physiol 2000;48:F302-F308.
35. Tesfamariam B, Ogletree ML. Dissociation of endothelial cell dysfunction and blood pressure in SHR. Am J Physiol. 1995;269:H189-H194.
36. Chabrashvili T, Tojo A, Onozato M, Kitiyakara C, Quinn MT, Fujita T, Welch WJ, Wilcox CS. Expression and cellular localization of classic NADPH oxidase subunits in the spontaneously hypertensive rat kidney. Hypertens. 2001;39:269-274.
37. Zaugg CE, Hornstein PS, Zhu P, Simper D, Luscher TF, Allegrini PR, Buser PT. Endothelin-1-induced release of thromboxane A2 increases the vasoconstrictor effect of endothelin-1 in postischemic reperfused rat hearts. Circ. 1996;94:742-747.
38. Skov K, Mulvany MJ. Remodeling of the renal resistance vessels in hypertension. Adv Org Biol. 2000;9:331-346.
39. Chakraborti S, Gurtner GH, Michael JR. Oxidant-mediated activation of phospholipase A2 in pulmonary endothelium. Am J Physiol. 1989;257:L430-L437.
40. Valentin F, Field MC, Tippins JR. The mechanism of oxidative stress stabilization of the thromboxane receptor in COS-7 cells. J Bio Chem. 2004;279:8316-8324.
41. Ruef J, Moser M, Kübler W, Bode C. Induction of endothelin-1 expression by oxidative stress in vascular smooth muscle cells. Cardiovasc Pathol. 2001;10:311-315.
42. Takayasu-Okishio M, Terashita ZI, Kondo K. Endothelin-1 and platelet activating factor stimulate thromboxane A2 biosynthesis in rat vascular smooth muscle cells. Biochem Pharmacol. 1990;40:2713-2717.
43. Ungvari Z, Koller A. Endothelin and prostaglandin H2/thromboxane A2 enhance myogenic constriction in hypertension by increasing Ca2+ sensitivity of arteriolar smooth muscle. Hypertens 2000;36:856-861.
44. Gerzanich V, Ivanova S, Zhou H, Simard JM. Mislocalization of eNOS and upregulation of cerebral vascular Ca2+ channel activity in angiotensin- hypertension. Hypertens. 2003;41:1124-1130.
45. Harris RC, Breyer MD. Physiological regulation of cycooxygenase-2 in the kidney. Am J Physiol Renal Physiol. 2001;281:F1-F11.
46. Hu ZW, Kerb R, Shi XY, Wei-Lavery T, Hoffman BB. Angiotensin II increases expression of cyclooxygenase-2 implications for the function of vascular smooth muscle cells. J Pharmacol Exp Ther. 2002;303:563-573.
47. Leslie C. C. Properties and regulation of cytosolic phospholipase A2. J Biol Chem. 1997;272:16709-16712.
48. francois H, Athirakul K, Rockman H, Coffman TM. Role for thromboxane receptors in angiotensin-II-induced hypertension. Hypertens. 2004;43:364-369.
49. Yamaguchi T, Fenoy FJ, Roman RJ, Nasjletti A. Angiotensin II influences the renal hemodynamic response to blockade of thromboxane A2 and prostaglandin H2 receptors. J Pharmacol Exp Ther. 1992;263:905-909.
50. Park SJ, Lee JJ, Vanhouette PM. Endothelin-1 releases endothelium-derived endoperoxides and thromboxane A2 in porcine coronary arteries with generated endothelium. Acta Pharmacol Sin. 1999;20:872-878.
51. Thorup C, Kornfeld M, Winaver JM, Goligorsky MS, Moore LC. Angiotensin-II stimulates nitric oxide release in isolated perfused renal resistance arteries. Pflugers Arch Eur J Physiol. 1998;435:432-434.
52. Schnackenberg CG, Welch WJ, Wilcox CS. Normalization of blood pressure and renal vascular resistance in SHR with a membrane-permeable superoxide dismutase mimetic: Role of nitric oxide. Hypertens. 1998;32:59-64.